ArticleScientific reports2025
Log odds of positive lymph nodes as a prognostic marker in resectable triple negative breast cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The clinical relevance of LODDS for post-mastectomy radiotherapy in T1-2N1M0 breast cancer: a real-world propensity score-weighted analysis using the SEER database.Gland surgery · 2026Article
- Prognostic value of metastatic lymph-node ratio and log-odds of positive nodes after neoadjuvant chemotherapy in breast cancer.World journal of surgical oncology · 2026Article
- Oncologic safety of breast-conserving surgery in node-positive breast cancer: a systematic review and meta-analysis.Gland surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to assess the prognostic value of the log odds of positive lymph nodes (LODDS) in resectable nonmetastatic triple-negative breast cancer (TNBC) and its potential role in informing postoperative treatment decisions. A retrospective cohort study was conducted using data from the SEER 17 registries, including patients aged 20-79 diagnosed with TNBC. The association between LODDS and cancer-specific survival (CSS) was analyzed using the restrictive cubic splines (RCS) method. Propensity score matching (PSM) and survival analysis were employed to evaluate the effect of LODDS on treatment outcomes. Between 2010 and 2021, breast-conserving surgery (BCS) emerged as the predominant surgical approach for resectable nonmetastatic TNBC, with its proportion increasing from 49.3 to 52.1%, while mastectomy rates declined from 46.5 to 38.9%. RCS analysis identified a significant nonlinear association (p < 0.001) between LODDS and CSS, with a threshold value of -1.6 effectively categorizing patients into low-risk (LODDS < -1.6) and high-risk (LODDS > -1.6) groups. Patients in the low-risk group exhibited superior survival, with 5-year and 10-year CSS rates improving by 7.3% and 8.4%, respectively, following PSM. Notably, BCS was associated with better survival outcomes compared to mastectomy, particularly in high-risk LODDS patients. Stratified analysis by LODDS and age revealed that BCS followed by radiotherapy conferred the most substantial survival benefit. LODDS is a reliable prognostic marker for survival outcomes in resectable nonmetastatic TNBC. Incorporating LODDS into age-based risk stratification can facilitate more personalized postoperative management following BCS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.